SERUM-ALBUMIN AND OTHER PROGNOSTIC FACTORS RELATED TO RESPONSE AND SURVIVAL IN PATIENTS WITH ADVANCED NONSMALL CELL LUNG-CANCER
SERUM-ALBUMIN AND OTHER PROGNOSTIC FACTORS RELATED TO RESPONSE AND SURVIVAL IN PATIENTS WITH ADVANCED NONSMALL CELL LUNG-CANCER
复制标题
DOI：
10.1016/0169-5002(95)00407-r
复制
发表时间：
1995-03-01
期刊：
影响因子：
5.3
通讯作者：
ESPINOSA, J
中科院分区：
文献类型：
--
作者：
ESPINOSA, E;FELIU, J;ESPINOSA, J
晚期非小细胞肺癌（NSCLC）的标准治疗仍有待确定。化疗的不良结果有利于寻找有助于识别更有可能应答的患者的预后因素。我们的目标是寻找与晚期非小细胞肺癌患者的缓解、缓解持续时间和总生存期相关的因素。我们回顾了292例不可手术的NSCLC患者的临床记录，所有患者均具有良好的体能状态并接受了化疗。90%为男性，中位年龄为59岁。治疗方案包括MACC（甲氨蝶呤、阿霉素、环磷酰胺和环己亚硝脲）、顺铂+长春地辛或依托泊苷、MIP（丝裂霉素、异环磷酰胺和顺铂）和MVP（丝裂霉素、长春地辛和顺铂）。在多变量分析中，正常白蛋白水平和顺铂的纳入与缓解的实现相关（如果两个有利因素均存在，则为40%）。没有出现与缓解持续时间相关的因素。以下因素可预测生存率：体重减轻、体能状态、淋巴细胞计数、白蛋白水平、转移瘤数量和骨转移瘤的存在。我们的结论是，白蛋白水平确定了一组晚期NSCLC患者谁是更有可能响应含顺铂化疗。
The standard therapy for advanced non-small cell lung cancer (NSCLC) remains to be defined. The poor results from chemotherapy have favored the search for prognostic factors that help identify patients more likely to respond. Our objective was to find factors related to response, the duration of response, and overall survival in patients with advanced NSCLC. We reviewed the clinical records of 292 patients with non-operable NSCLC, ail of whom had a good performance status and had received chemotherapy. Ninety percent were male and the median age was 59 years. The therapeutic regimens included MACC (methotrexate, adriamycin, cyclophosphamide and CCNU), cisplatin + vindesine or etoposide, MIP (mitomycin, ifosfamide and cisplatin) and MVP (mitomycin, vindesine and cisplatin). In the multivariate analysis, a normal albumin level and the inclusion of cisplatin were related to the achievement of a response (40% if both favorable factors were present). No factors appeared related to the duration of response. The following factors were predictive for survival: weight loss, performance status, lymphocyte count, albumin level, number of metastases and the presence of bone metastases. We conclude that the albumin level identifies a group of patients with advanced NSCLC who are more likely to respond to cisplatin-containing chemotherapy.